<DOC>
	<DOCNO>NCT02600351</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fix dose combination ( FDC ) 12 week without ribavirin ( RBV ) participant without cirrhosis , LDV/SOF FDC 12 week RBV LDV/SOF FDC 24 week without RBV participant cirrhosis .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir , With Without Ribavirin , HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>HCV RNA &gt; 15 IU/mL screen HCV genotype 1 4 Chronic HCV infection ( ≥ 6 month ) Prior virologic failure treatment SOF combination simeprevir ( SMV ) ± RBV RBV ± PEG Cirrhotic noncirrhotic determine standard method Male female individual childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Prior exposure approve experimental nonstructural protein ( NS5A ) inhibitor Prior exposure nucleos ( ) ide polymerase inhibitor , SOF Pregnant nurse female male pregnant female partner Coinfection HIV hepatitis B virus Current prior history clinical hepatic decompensation Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>Ledipasvir/Sofosbuvir</keyword>
	<keyword>Ribavirin</keyword>
</DOC>